Teva Clinches Third Place In CGRP Race With A Phase III Migraine Win

 
• By Mandy Jackson

With a likely third place finish in the race to bring a CGRP inhibitor to market for the prevention of migraine headaches, Teva needs something to differentiate its product. Quarterly subcutaneous dosing may help fremanezumab become a fan favorite.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from Clinical Trials

More from R&D